癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响*

doi:10.3969/j.issn.1672-5069.2022.06.032

Abstract

Abstract: Objective This study was to explore the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy and sorafenib therapy by cancerous N⁶-methylpurine (M6A) methyltransferase-like protein 3 (METTL3) levels. Methods A total of 62 patients with HCC were enrolled in our hospital between August 2016 and August 2019, and all patients underwent hepatectomy, receiving sorafenib therapy after operation and followed-up for two years. The cancerous and non-cancerous tissue METL3 mRNA levels were detected by qRT-PCR. The prognostic value of cancerous METL3 mRNA was analyzed by area under the receiver operating characteristic (ROC) curves (AUC). Results The cancerous METL3 mRNA level was significantly higher than that in adjacent tissues [(7.7±1.4) vs. (5.3±1.1), P<0.05]; the cancerous METL3 mRNA levels in patients with tumor diameter ≥5 cm, TNM stage Ⅲ and with extrahepatic metastasis were (8.1±1.1), (8.2±1.4)and (8.6±0.8), all significantly higher than [(7.0±0.9), (7.3±0.7)and (7.4±1.2), P<0.05] in patients with tumor diameter <5 cm, TNM staging stage Ⅰ-Ⅱ and without extrahepatic metastasis (P＜0.05); at the end of two-year follow-up, 27 patients survived and 35 died; the cancerous METTL3 mRNA level in survived patients was (7.0±1.0), significantly lower than [(8.2±1.1), P＜0.05] in died ones; the AUC was 0.712 [95%CI(0.584-00.839)] when the optimal cut-off-value of cancerous METTL3 mRNA level was set at 7.6, with the sensitivity, specificity and accuracy of 71.4%, 66.7% and 69.4%; the total survival in patients with lower cancerous METTL3 mRNA levels was 64.3%, significantly higher than 26.5%(P＜0.05) in those with high cancerous METTL3 mRNA levels. Conclusion The cancerous METTL3 mRNA levels in patients with HCC is up-regulated, and the cancerous METTL3 mRNA level is correlated to tumor diameter, TNM staging and extrahepatic metastasis. The surveillance of cancerous METTL3 mRNA levels might help predict the prognosis of HCC patients receiving sorafenib therapy after hepatectomy.

Key words: Hepatocellular carcinoma, Hepatectomy, Sorafenib, N⁶-methylpurine, Methyltransferase-like protein 3, Prognosis

Gao Zhengxing, Li Guangxin, Song Chunqing. Prognosis of patients with hepatocellular carcinoma after hepatectomy and sorafenib therapy: prediction by cancerous M6A methyltransferase-like protein 3 levels[J]. Journal of Practical Hepatology, 2022, 25(6): 885-888.

References

[1] 陈静,余君铭,刘腾飞,等.沉默EFNA3基因水平抑制缺氧诱导的肝细胞癌细胞的迁移与侵袭.肿瘤,2020,327(5):7-18.
[2] Perfahl H, Jain HV, Joshi T, et al. Hybridmodelling of transarterial chemoembolisation therapies (TACE) for hepatocellular carcinoma (HCC). Sci Rep, 2020,10(1):10571.
[3] Raghav K, Lee RT , Paluri RK, et al. An open-label phase Ib/2 trial of TRC105 plus sorafenib in patients with advanced/metastatic hepatocellular carcinoma (HCC) . J Clin Oncol,2019, 37(4):268.
[4] Wu Z, Shi Y, Lu M, et al. METTL3 counteracts premature aging via m6A-dependent stabilization of MIS12 mRNA. Nucl Acid Res, 2020,48(19):11083-11096.
[5] Wu Y, Chang N, Zhang Y, et al. METTL3-mediated m6A mRNA modification of FBXW7 suppresses lung adenocarcinoma. J Exp Clin Cancer Res, 2021,40(1):90.
[6] Qin Y, Qiao Y, Li L, et al. The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension. Life Sci, 2021, 274(10):119366.
[7] Dahal U, Kang L, Gupta M. RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res, 2019,8(1):65-69.
[8] Wu H, Li F, Zhu R. miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer. Acta Bioch Bioph Sin, 2020,53(3):304-316.
[9] Tzelepis K, Braekeleer ED, YankovaE, et al. Pharmacological inhibition of the RNA m6a writer METTL3 as a novel therapeutic strategy for acute myeloid leukemia. Blood, 2019,134(1):403-405.
[10] 李显永,官润云,柯坤彬,等.甲基转移酶3在前列腺癌中的水平及其临床意义.实用医学杂志, 2019,35(1):75-79.
[11] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志, 2011,16(10):71-88.
[12] 王虎明,樊东升,徐杰,等.肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨.实用肝脏病杂志,2019,22(2):248-251.
[13] Jiang H, Ning G, Wang Y, et al. Identification of an m6A-related signature as biomarker for hepatocellular carcinoma prognosis and correlates with sorafenib and anti-PD-1 immunotherapy treatment response. Dis Markers, 2021,24(3):1-15.
[14] Cao Z, Zhang L, Hong R,et al. METTL3-mediated m6A methylation negatively modulates autophagy to support porcine blastocyst development. Biol Reprod,2021,104(5):22-24.
[15] Liu S, Li Q, Li G, et al. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis, 2020,11(11):969.
[16] Hong WA, Bei XB, Js C. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.Gene, 2020,722(5):144-146.
[17] Lubbock A, Stewart GD, Mahony FC. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Med, 2017,15(1):118-127.
[18] Yao MD, Jiang Q, Ma Y, et al. Role of METTL3-dependent N6-methyladenosine mRNA modification in the promotion of angiogenesis. Mol Ther, 2020,28(10):2191-2202.
[19] ChengC, Wu Y, Xiao T, et al. METTL3-mediated m6A modification of ZBTB4 mRNA is involved in the smoking-induced EMT in cancer of the lung - science direct. Mol Ther Nucl Acid, 2021,23(5):487-500.
[20] 方义杰, 潘洁琳, 卢慧芳,等. 应用肿瘤三维体积测量早期评估肝细胞癌索拉非尼靶向治疗疗效的可行性及可重复性. 中华放射学杂志, 2019,53(2):133-137.

Prognosis of patients with hepatocellular carcinoma after hepatectomy and sorafenib therapy: prediction by cancerous M6A methyltransferase-like protein 3 levels

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Rong, Cao Jingjing, Li Jing, et al.. Triggering and impacting factors of prognosis in patients with hepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2022, 25(6): 832-835.
[2]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[3]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[4]	Shi Qingchun, Pan Limin, Bu Fan, et al.. TCGA-based study of cell necrosis-related genes as prognostic indicators in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 869-872.
[5]	Zheng Xiyan, Du Fei, Lin Zhiqun, et al.. Metabolic syndrome-related risk factor for disease progression of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 877-880.
[6]	Cui Po, Dong Shiming, Nan Yuemin. Prognosis of COVID-19 patients with underlying chronic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 905-908.
[7]	Wang Qian, Li Wenli, Wang Bing, et al.. Clinical characteristics of patients with Dengue fever: A report of 70 cases [J]. Journal of Practical Hepatology, 2022, 25(5): 645-648.
[8]	Liu Yan, Shen Yu,Zhang Qian. Characteristics and clinical outcomes of 60 patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(5): 649-652.
[9]	Wang Mingqiang, Niu Yaofei, Wang Shengfeng. Serum clusterin levels in patients with hepatitis B virus-related acute-on-chronic liver failure and its correlation with short-term prognosis [J]. Journal of Practical Hepatology, 2022, 25(5): 677-680.
[10]	Wu Tong, Zhang Qiaoli, Qi Xuewei. Systematic analysis of functions of RNA-binding proteins in hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(5): 693-697.
[11]	Fan Shunke, Wang Guiluo,Yi Xiaoyan. Different dosage of sevoflurane and propofol combination venous-inhalation anesthesia in patients with primary liver cancer undergoing radical hepatectomy [J]. Journal of Practical Hepatology, 2022, 25(5): 702-705.
[12]	Jiang Lina, Tian Hui, Yuan Zhijun, et al.. Prognosis of patients with gallbladder cancer by serum vascular endothelial growth factor C levels [J]. Journal of Practical Hepatology, 2022, 25(5): 746-749.
[13]	Bu Fan, Chai Jianbo, Bai Bing, et al. Cyber-based study on ferroptosis-related long non-coding RNA signature predicting prognosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(4): 558-562.
[14]	Lin Yikun, Xie Lang, Fu Jianming, et al. Clinical efficacy of partial hepatectomy and choledochojejunostomy combination in the treatment of patients with hepatolithiasis and risk factors for postoperative recurrence [J]. Journal of Practical Hepatology, 2022, 25(4): 591-594.
[15]	Sun Yanan, Zeng Qinghuan, Liu Yuanzhi, et al. Influencing factors for prognosis of patients with acute-on-chronic liver failure and moderate or severe esophageal varices [J]. Journal of Practical Hepatology, 2022, 25(3): 391-394.